Search the Newsreel

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Silence Therapeutics closes $201.3M public offering By Investing.com

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company …

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Coeur Mining, Inc. $CDE Shares Sold by Handelsbanken Fonder AB

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Handelsbanken Fonder AB Reduces Stock Holdings in Weyerhaeuser Company $WY

Handelsbanken Fonder AB reduced its stake in Weyerhaeuser Company (NYSE:WY) by 17.9% in the second quarter, selling 48,885 shares and retaining 223,900 shares valued at $5.36 million. Despite the reduction, institutional investors collectively own 82.99% of Weyerhaeuser. The company reported strong quarterly earnings, beating …

National Energy Services Reunited (NESR), Why Is It Back In The Spotlight?

National Energy Services Reunited (NESR) is gaining attention after strong Q2 2026 earnings, increased sales, and new contracts in the Middle East. The company's stock price has shown significant momentum, with a 90-day return of 42.62%. While a valuation model suggests the stock is …

XS3324770646 Bond Yield and Price — LUXSE:XS3324770646

This article provides detailed information on the Deutsche Bank Aktiengesellschaft 4.6% 13-AUG-2031 bond, identified by ISIN XS3324770646, traded on the Luxembourg Stock Exchange. It covers key terms such as outstanding amount, face value, coupon rate, and maturity date, along with issuer details and a …

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts

Gain Therapeutics (NASDAQ:GANX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.50. The company recently reported a narrower-than-expected quarterly loss of $0.11 per share. Institutional investors hold a significant portion of GANX stock, with several firms …

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss …

Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN

Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Viking Therapeutics Inc (VKTX) News, Articles, Events & Latest Updates

Euro India Fresh Foods Ltd is Rated Sell

Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy?

Liquidity Mapping Around (APGE) Price Events

This article provides a detailed liquidity mapping analysis for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies including long, momentum breakout, and short positions with specific entry, target, and stop-loss levels. …

T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G

T. Rowe Price Associates, Inc. has disclosed a 5.2% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN) through a Schedule 13G SEC filing. As of June 30, 2026, the firm holds 5,748,426 shares of common stock, with sole voting power over 5,748,380 shares and …

Aberdeen Group plc Acquires 125,264 Shares of Weyerhaeuser Company $WY

Aberdeen Group plc increased its stake in Weyerhaeuser Company (NYSE:WY) by 13.8% in the second quarter, purchasing an additional 125,264 shares, bringing its total holdings to over 1 million shares valued at $24.7 million. Weyerhaeuser maintains a "Moderate Buy" consensus rating with an average …

Weyerhaeuser Company $WY Shares Purchased by AIA Group Ltd

AIA Group Ltd significantly increased its stake in Weyerhaeuser Company (NYSE:WY) by 92.4% in the second quarter, acquiring an additional 343,414 shares, bringing its total to 714,991 shares valued at $17.1 million. The article notes that institutional investors own a substantial 82.99% of WY …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Thomson Reuters (TSE:TRI) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics (OTLK) stock has seen a significant decline over the past five years, despite the recent FDA approval and upcoming launch of LYTENAVA. The company's valuation scores poorly, indicating it's not a bargain, and its balance sheet shows a negative book value, making …

Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold

Wall Street Zen has upgraded Cardiol Therapeutics (NASDAQ:CRDL) from a "Sell" to a "Hold" rating, aligning with the overall average "Hold" rating from analysts and an $8.50 price target. CRDL shares rose 5.3% to $1.80, with a market cap of $208.6 million, and the …

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

Rein Therapeutics (NASDAQ:RNTX) reported stronger-than-expected quarterly earnings, with an EPS of $(0.10) significantly beating the consensus estimate of $(0.27). Following the announcement, the stock saw a modest increase of 2.3% to $0.81, though it remains below its 12-month high. The company, focused on developing …

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen

Wall Street Zen has upgraded Unicycive Therapeutics (NASDAQ:UNCY) from a "sell" to a "hold" rating, contributing to a mixed analyst consensus of "Hold" with a $18.25 price target. Despite several firms like Benchmark and HC Wainwright maintaining bullish ratings but cutting price targets, and …

Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?

Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded Maze Therapeutics (NASDAQ:MAZE) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $66.00. The company's shares opened at $27.18, representing a 1.8% decrease and significantly below its 52-week high …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Lexeo Therapeutics (NASDAQ:LXEO) from a "hold" to a "strong sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $18.75. The company's shares opened at $4.84, near its 12-month low, and it reported a …

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …